ALISO VIEJO, Calif., Nov. 19, 2015 /PRNewswire/ -- Sentrian, the Remote Patient Intelligence™ company aspiring to eliminate all preventable hospitalization, has been selected as a finalist in this year's Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher of FierceHealthIT, FierceHealthcare, and FierceMobileHealthcare.
Sentrian was recognized as a finalist in the category of Digital/Mobile Health Solutions for its Remote Patient Intelligence (RPI) solution. Sentrian RPI is designed to reduce avoidable hospitalization by leveraging the revolution in biosensors and machine learning to remotely detect health deterioration in high-risk patients earlier and with higher accuracy. That enables lower-cost interventions to be utilized before the patient becomes acute and requires hospitalization.
"We are honored to be recognized as a finalist in the Fierce Innovation Awards," said Sentrian CEO Dean Sawyer. "This recognition is validation of the importance of the work we're undertaking with our customers in applying advanced analytics to remote biometric data streams. We believe the technology will drive significant reductions in hospitalization while increasing the efficiency of remote care teams – accomplishments that will help our healthcare system cope with the crushing expense of caring for the chronically ill."
Finalists were selected by a distinguished panel of CIOs from renowned U.S. hospitals and healthcare systems, including Allina Health, Rush University Medical Center, Aspirus, and JFK Health System, among others. A complete list of judges can be found at https://www.fierceinnovationawards.com/healthit/2015#our_judges.
All applications were evaluated based on the following criteria: care efficiency, competitive advantage, financial impact/value, market need, patient experience/satisfaction, quality of care and patient outcomes, and overall fierceness and innovation. Finalists were selected based on calculation of the judges' scores in each area.
To learn more about Sentrian, visit www.Sentrian.com.
FierceMarkets, a division of Questex, LLC, is a leader in B2B e-media, providing information and marketing services in the telecommunications, life sciences, healthcare and technology industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets' wide array of digital publications reaches more than 2 million executives in more than 100 countries.
Current publications include: Telecom: FierceWireless; FierceCable; FierceDeveloper; FierceOnlineVideo; FierceTelecom; FierceWirelessTech; FierceWireless:Europe /TelecomsEMEA, FierceInstaller; Smart Grid News; and Telecom Asia; Healthcare: FierceEMR; FierceHealthcare; FierceHealthFinance; FierceHealthIT; FierceHealthPayer; FierceHealthPayerAntiFraud; FierceMobileHealthcare; FiercePracticeManagement and Hospital Impact; Life Sciences: FierceAnimalHealth; FierceBiotech; FierceBiotechIT; FierceBiotechResearch; FierceCRO; FierceDiagnostics, FierceDrugDelivery; FierceMedicalDevices; FiercePharma; FiercePharmaAsia; FiercePharmaMarketing; FiercePharmaManufacturing; and FierceVaccines; Technology: FierceBigData; FierceCIO; FierceCities; FierceContentManagement; FierceDevOps; FierceEnterpriseCommunications; FierceFinanceIT; FierceGovernmentIT; FierceITSecurity; FierceMobileIT; ; FierceCMO; and FierceRetail.
Sentrian™, the Remote Patient Intelligence™ company aspiring to eliminate all preventable hospitalization, was founded to help "at-risk" organizations improve their shared savings performance by reducing hospitalization in their highest risk patients. The Sentrian end-to-end remote patient intelligence solution leverages the revolution in wearable, multi-modal biosensors and machine learning to detect health deterioration in high-risk patients earlier and with higher accuracy so lower-cost interventions can be utilized before the patient becomes acute and requires hospitalization. Early evidence has shown that Sentrian RPI can detect deterioration leading to a hospitalization at nearly double the accuracy of first-generation remote patient monitoring. The Sentrian solution is commercially available, FDA 510K exempt and designed to seamlessly integrate with existing healthcare information systems and clinical workflows, facilitating adoption. To learn more about Sentrian, visit www.Sentrian.com.
Amendola Communications for Sentrian